Anti-interleukin-1 therapy with canacinumab and anakinra in patients with histologically proven AA amyloidosis secondary to Familial Mediterranean Fever

Trial Profile

Anti-interleukin-1 therapy with canacinumab and anakinra in patients with histologically proven AA amyloidosis secondary to Familial Mediterranean Fever

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Aug 2016

At a glance

  • Drugs Canakinumab (Primary) ; Anakinra; Colchicine
  • Indications Familial Mediterranean fever
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top